MedTrace Logo

Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis

NCT07706998 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-07-16

No results posted yet for this study

Summary

Aim:

To evaluate the application effect of the teaching platform iLN in the teaching of lupus nephritis, aiming to provide practical experience and evidence-based support for the implementation of generative AI technology in professional medical education.

Method:

Based on the DeepSeek large language model, the investigators developed "iLN" - an interactive teaching platform for lupus nephritis. This platform integrates the latest authoritative textbooks, clinical guidelines, pathological atlases, and real clinical cases, and includes seven core modules, such as "case interaction", "knowledge teaching", and "AI question answering". The investigators conducted a randomized controlled trial (RCT) on 50 fourth-year undergraduate students from Nanjing University School of Medicine to evaluate the effectiveness of the iLN platform compared to traditional teaching methods. The teaching effect was evaluated through objective test scores and questionnaires about student satisfaction and platform usability.

Conditions

  • Learning

Interventions

DEVICE

An iLN interactive teaching platform

An iLN interactive teaching platform for lupus nephritis based on the DeepSeek large language model and by integrating the latest authoritative textbooks, guidelines, and clinical pathology materials.

OTHER

PPT

Adopted the traditional PowerPoint (PPT) lecture mode. The instructor used uniformly prepared PPT courseware to sequentially lecture on the SLE overview, LN clinical manifestations, laboratory tests, pathological classification, diagnostic criteria, treatment plans, and prognosis evaluation. The courseware included static pathological and clinical manifestation images.

Sponsors & Collaborators

  • Nanjing University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706998 on ClinicalTrials.gov